The pharmacogenomics journal

Keyphrases

Publications

volume 24, number 3, 2024

Yitian Zhou, Sebastian Pirmann, Volker Martin Lauschke
APF2: an improved ensemble method for pharmacogenomic variant effect prediction. The pharmacogenomics journal 24 (3) (2024)
Jianchang Qian, Tao Xu, Peipei Pan, Wei Sun, Guo-Xin Hu, Jianping Cai
Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug. The pharmacogenomics journal 24 (3) (2024)
Daniel Thomas Barratt, Pål Klepstad, Ola Dale, Stein Kaasa, Andrew Alexander Somogyi
Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects. The pharmacogenomics journal 24 (3) (2024)
Daniel Thomas Barratt, Pål Klepstad, Ola Dale, Stein Kaasa, Andrew Alexander Somogyi
Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects. The pharmacogenomics journal 24 (3) (2024)
Deniz Türkmen, Jack Bowden, Jane A H Masoli, João Delgado, Chia-Ling Kuo, David Melzer, Luke C Pilling
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone. The pharmacogenomics journal 24 (3) (2024)
Daniel Thomas Barratt, Pål Klepstad, Ola Dale, Stein Kaasa, Andrew Alexander Somogyi
Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects. The pharmacogenomics journal 24 (3) (2024)
Yitian Zhou, Sebastian Pirmann, Volker Martin Lauschke
APF2: an improved ensemble method for pharmacogenomic variant effect prediction. The pharmacogenomics journal 24 (3) (2024)
Yitian Zhou, Sebastian Pirmann, Volker Martin Lauschke
APF2: an improved ensemble method for pharmacogenomic variant effect prediction. The pharmacogenomics journal 24 (3) (2024)
Yitian Zhou, Sebastian Pirmann, Volker Martin Lauschke
APF2: an improved ensemble method for pharmacogenomic variant effect prediction. The pharmacogenomics journal 24 (3) (2024)
Jianchang Qian, Tao Xu, Peipei Pan, Wei Sun, Guo-Xin Hu, Jianping Cai
Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug. The pharmacogenomics journal 24 (3) (2024)
Penezić Luka, Sandra Nađ-Škegro, Ayla Hadžavdić, Lana Ganoci, Željko Kaštelan, Vladimir Trkulja, Nada Božina
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppression. The pharmacogenomics journal 24 (3) (2024)
Deniz Türkmen, Jack Bowden, Jane A H Masoli, João Delgado, Chia-Ling Kuo, David Melzer, Luke C Pilling
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone. The pharmacogenomics journal 24 (3) (2024)
Yi-Chieh Chen, Han Wang, Jayawant N Mandrekar, Carrie E Robertson, Amaal J Starling, Fred M Cutrer, Chia-Chun Chiang
Pharmacogenomic study-A pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of verapamil for migraine prevention. The pharmacogenomics journal 24 (3) (2024)
Lorenzo Chidiac, Hady Yazbeck, Rami Mahfouz, Nathalie Khoueiry Zgheib
Pharmacogenomics in Lebanon: current status, challenges and opportunities. The pharmacogenomics journal 24 (3) (2024)
Daniel Thomas Barratt, Pål Klepstad, Ola Dale, Stein Kaasa, Andrew Alexander Somogyi
Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects. The pharmacogenomics journal 24 (3) (2024)
Kimberly M Deininger, Heather D Anderson, George P Patrinos, Christina Mitropoulou, Christina L Aquilante
Cost-effectiveness analysis of CYP3A5 genotype-guided tacrolimus dosing in solid organ transplantation using real-world data. The pharmacogenomics journal 24 (3) (2024)
Penezić Luka, Sandra Nađ-Škegro, Ayla Hadžavdić, Lana Ganoci, Željko Kaštelan, Vladimir Trkulja, Nada Božina
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppression. The pharmacogenomics journal 24 (3) (2024)
Yi-Chieh Chen, Han Wang, Jayawant N Mandrekar, Carrie E Robertson, Amaal J Starling, Fred M Cutrer, Chia-Chun Chiang
Pharmacogenomic study-A pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of verapamil for migraine prevention. The pharmacogenomics journal 24 (3) (2024)
Yitian Zhou, Sebastian Pirmann, Volker Martin Lauschke
APF2: an improved ensemble method for pharmacogenomic variant effect prediction. The pharmacogenomics journal 24 (3) (2024)
Deniz Türkmen, Jack Bowden, Jane A H Masoli, João Delgado, Chia-Ling Kuo, David Melzer, Luke C Pilling
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone. The pharmacogenomics journal 24 (3) (2024)
Lorenzo Chidiac, Hady Yazbeck, Rami Mahfouz, Nathalie Khoueiry Zgheib
Pharmacogenomics in Lebanon: current status, challenges and opportunities. The pharmacogenomics journal 24 (3) (2024)
Deniz Türkmen, Jack Bowden, Jane A H Masoli, João Delgado, Chia-Ling Kuo, David Melzer, Luke C Pilling
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone. The pharmacogenomics journal 24 (3) (2024)
Jianchang Qian, Tao Xu, Peipei Pan, Wei Sun, Guo-Xin Hu, Jianping Cai
Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug. The pharmacogenomics journal 24 (3) (2024)
Kimberly M Deininger, Heather D Anderson, George P Patrinos, Christina Mitropoulou, Christina L Aquilante
Cost-effectiveness analysis of CYP3A5 genotype-guided tacrolimus dosing in solid organ transplantation using real-world data. The pharmacogenomics journal 24 (3) (2024)
Deniz Türkmen, Jack Bowden, Jane A H Masoli, João Delgado, Chia-Ling Kuo, David Melzer, Luke C Pilling
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone. The pharmacogenomics journal 24 (3) (2024)

volume 24, number 4, 2024

Adriana Vázquez-Medina, Marion T Turnbull, Courtney L James, Jennifer B Cowart, Elizabeth Lesser, Rickey E Carter, Owen A Ross, David A Miller, James F Meschia, Aixa De Jesús Espinosa, Richard Weinshilboum, William David Freeman
Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics. The pharmacogenomics journal 24 (4) (2024)
Lily K Stafford, Xiaohui Tang, Amanda Brandt, Jianzhong Ma, Jose Banchs, Jonathan A Livingston, Michael E Roth, Alanna C Morrison, Michelle A T Hildebrandt
Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci. The pharmacogenomics journal 24 (4) (2024)
Juliana Salazar, Pau Riera, Jordi Gordillo, Albert Altès, Miguel Martínez, Montserrat Serès, Jordina Llaó, Antonio Giordano, Esther Garcia-Planella
Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn's disease patients. The pharmacogenomics journal 24 (4) (2024)
Jon E Sprague, Caroline E Freiermuth, Joshua Lambert, Robert Braun, Jennifer A Frey, Daniel J Bachmann, Jason J Bischof, Lauren Beaumont, Michael S Lyons, Michael V Pantalon, Brittany E Punches, Rachel Ancona, David F Kisor
Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females. The pharmacogenomics journal 24 (4) (2024)
Julia Coelho França Quintanilha, William Kevin Kelly, Federico Innocenti
Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension. The pharmacogenomics journal 24 (4) (2024)
Julia Coelho França Quintanilha, William Kevin Kelly, Federico Innocenti
Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension. The pharmacogenomics journal 24 (4) (2024)
Juliana Salazar, Pau Riera, Jordi Gordillo, Albert Altès, Miguel Martínez, Montserrat Serès, Jordina Llaó, Antonio Giordano, Esther Garcia-Planella
Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn's disease patients. The pharmacogenomics journal 24 (4) (2024)
Juliana Salazar, Pau Riera, Jordi Gordillo, Albert Altès, Miguel Martínez, Montserrat Serès, Jordina Llaó, Antonio Giordano, Esther Garcia-Planella
Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn's disease patients. The pharmacogenomics journal 24 (4) (2024)
Lily K Stafford, Xiaohui Tang, Amanda Brandt, Jianzhong Ma, Jose Banchs, Jonathan A Livingston, Michael E Roth, Alanna C Morrison, Michelle A T Hildebrandt
Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci. The pharmacogenomics journal 24 (4) (2024)
Jon E Sprague, Caroline E Freiermuth, Joshua Lambert, Robert Braun, Jennifer A Frey, Daniel J Bachmann, Jason J Bischof, Lauren Beaumont, Michael S Lyons, Michael V Pantalon, Brittany E Punches, Rachel Ancona, David F Kisor
Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females. The pharmacogenomics journal 24 (4) (2024)
Jon E Sprague, Caroline E Freiermuth, Joshua Lambert, Robert Braun, Jennifer A Frey, Daniel J Bachmann, Jason J Bischof, Lauren Beaumont, Michael S Lyons, Michael V Pantalon, Brittany E Punches, Rachel Ancona, David F Kisor
Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females. The pharmacogenomics journal 24 (4) (2024)
Jon E Sprague, Caroline E Freiermuth, Joshua Lambert, Robert Braun, Jennifer A Frey, Daniel J Bachmann, Jason J Bischof, Lauren Beaumont, Michael S Lyons, Michael V Pantalon, Brittany E Punches, Rachel Ancona, David F Kisor
Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females. The pharmacogenomics journal 24 (4) (2024)
Adriana Vázquez-Medina, Marion T Turnbull, Courtney L James, Jennifer B Cowart, Elizabeth Lesser, Rickey E Carter, Owen A Ross, David A Miller, James F Meschia, Aixa De Jesús Espinosa, Richard Weinshilboum, William David Freeman
Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics. The pharmacogenomics journal 24 (4) (2024)
Jon E Sprague, Caroline E Freiermuth, Joshua Lambert, Robert Braun, Jennifer A Frey, Daniel J Bachmann, Jason J Bischof, Lauren Beaumont, Michael S Lyons, Michael V Pantalon, Brittany E Punches, Rachel Ancona, David F Kisor
Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females. The pharmacogenomics journal 24 (4) (2024)
Julia Coelho França Quintanilha, William Kevin Kelly, Federico Innocenti
Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension. The pharmacogenomics journal 24 (4) (2024)

volume 24, number 5, 2024

Christine M Formea, Paldeep S Atwal, Kathryn Meintsma, Martin Dawes, Gary Marchant, Ben L Kong, J Shawn Jones, Sara L Rogers
STRIPE partners in precision medicine series: provider perspective. The pharmacogenomics journal 24 (5) (2024)
John Henry McDermott, Videha Sharma, Glenda M Beaman, Jessica Keen, William G Newman, Paul Wilson, Katherine Payne, Stuart Wright
Understanding general practitioner and pharmacist preferences for pharmacogenetic testing in primary care: a discrete choice experiment. The pharmacogenomics journal 24 (5) (2024)
Moataz Ehab Mohamed, Bin Guo, Baolin Wu, David P Schladt, Amutha Muthusamy, Weihua Guan, Juan E Abrahante, Guillaume C Onyeaghala, Abdelrahman Saqr, Nathan Pankratz, Gaurav Agarwal, Kymberly D Watt, Arthur J Matas, William S Oetting, Rory P Remmel, Ajay K Israni, Pamala A Jacobson, null null, Casey R Dorr
Extreme phenotype sampling and next generation sequencing to identify genetic variants associated with tacrolimus in African American kidney transplant recipients. The pharmacogenomics journal 24 (5) (2024)
Moataz Ehab Mohamed, Bin Guo, Baolin Wu, David P Schladt, Amutha Muthusamy, Weihua Guan, Juan E Abrahante, Guillaume C Onyeaghala, Abdelrahman Saqr, Nathan Pankratz, Gaurav Agarwal, Kymberly D Watt, Arthur J Matas, William S Oetting, Rory P Remmel, Ajay K Israni, Pamala A Jacobson, null null, Casey R Dorr
Extreme phenotype sampling and next generation sequencing to identify genetic variants associated with tacrolimus in African American kidney transplant recipients. The pharmacogenomics journal 24 (5) (2024)
Houyi Wei, Zhilong Li, Kaiyu Qian, Wenzhi Du, Lin-Gao Ju, Danni Shan, Mengxue Yu, Yayun Fang, Yi Zhang, Yu Xiao, Gang Wang, Xing-Huan Wang
Unveiling the association between HMG-CoA reductase inhibitors and bladder cancer: a comprehensive analysis using Mendelian randomization, animal models, and transcriptomics. The pharmacogenomics journal 24 (5) (2024)
John Henry McDermott, Videha Sharma, Glenda M Beaman, Jessica Keen, William G Newman, Paul Wilson, Katherine Payne, Stuart Wright
Understanding general practitioner and pharmacist preferences for pharmacogenetic testing in primary care: a discrete choice experiment. The pharmacogenomics journal 24 (5) (2024)
Moataz Ehab Mohamed, Bin Guo, Baolin Wu, David P Schladt, Amutha Muthusamy, Weihua Guan, Juan E Abrahante, Guillaume C Onyeaghala, Abdelrahman Saqr, Nathan Pankratz, Gaurav Agarwal, Kymberly D Watt, Arthur J Matas, William S Oetting, Rory P Remmel, Ajay K Israni, Pamala A Jacobson, null null, Casey R Dorr
Extreme phenotype sampling and next generation sequencing to identify genetic variants associated with tacrolimus in African American kidney transplant recipients. The pharmacogenomics journal 24 (5) (2024)
Ben L Kong, Roseann S Donnelly, Amina Abubakar, Henry M Dunnenberger, J Shawn Jones, Sara L Rogers, David F Kisor
STRIPE partners in precision medicine series: pharmacist perspective. The pharmacogenomics journal 24 (5) (2024)
John Henry McDermott, Videha Sharma, Glenda M Beaman, Jessica Keen, William G Newman, Paul Wilson, Katherine Payne, Stuart Wright
Understanding general practitioner and pharmacist preferences for pharmacogenetic testing in primary care: a discrete choice experiment. The pharmacogenomics journal 24 (5) (2024)
Sara L Rogers, J Shawn Jones, Ben L Kong, Christine M Formea, Jacob Awkal, Benjamin G Brown
A collaborative force for precision medicine progress: the STRIPE pharmacogenomics conference series. The pharmacogenomics journal 24 (5) (2024)